Allergan settles patent dispute with Amneal

Dublin-based pharmaceutical company Allergan has revealed that its subsidiaries, Forest Laboratories and Adamas Pharmaceuticals, have entered into a settlement agreement with Amneal Pharmaceuticals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

FTC hits Amneal, Impax and Endo with antitrust suit

28 January 2021 The US Federal Trade Commission is suing Endo Pharmaceuticals, Impax Laboratories, and Impax’s owner Amneal Pharmaceuticals, alleging that they were party to a 2017 agreement that violated antitrust law.

Americas

Amneal and Impax merge to become ‘fifth largest’ generics company

19 October 2017 Amneal Pharmaceuticals and Impax Laboratories have agreed to merge, in a deal the companies say will create the fifth largest generics drugs business in the US.

Americas

Allergan settles Restasis patent suit with InnoPharma, leaving three defendants

13 October 2017 Allergan and InnoPharma settled patent litigation over Restasis (cyclosporine ophthalmic emulsion) yesterday, October 12, leaving three defendants still involved in a much publicised case.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Allergan settles patent dispute with Amneal

More on this story

Editor's picks

Editor's picks

More features